PLEKHH1 inhibitors are chemical compounds designed to specifically target and inhibit the activity of the Pleckstrin homology domain-containing family H member 1 (PLEKHH1) protein. PLEKHH1 is a multifunctional protein associated with cytoskeletal organization and cellular signaling pathways. It contains a Pleckstrin homology (PH) domain, which is responsible for interactions with phosphoinositide lipids in the plasma membrane, and a Ras-association (RA) domain, which is important for binding to small GTPases. The precise biological function of PLEKHH1 is still being elucidated, but it is known to play a role in regulating cellular structure and movement, particularly in its ability to mediate actin dynamics and influence cell migration processes. PLEKHH1 inhibitors, therefore, serve as valuable tools in probing the protein's role in various biochemical pathways and understanding how its activity influences cellular architecture and signaling cascades.
From a chemical perspective, the development of PLEKHH1 inhibitors involves the design of molecules that can effectively bind to the protein's active or regulatory sites, disrupting its ability to interact with phosphoinositides or other signaling molecules. These inhibitors are typically small molecules with specific structural features that allow them to achieve high specificity and affinity for PLEKHH1, thereby reducing off-target interactions. The design process often involves structure-activity relationship (SAR) studies, where different chemical groups are modified to optimize binding efficacy and selectivity. Understanding the molecular interactions between PLEKHH1 and its inhibitors contributes to broader insights into the protein's conformational changes and the downstream effects of its inhibition on cytoskeletal dynamics and intracellular signaling. Research into PLEKHH1 inhibitors provides critical information for advancing our understanding of cellular mechanisms dependent on this protein, particularly those involving actin polymerization and cytoskeletal reorganization.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that affects various kinases involved in signaling pathways. Inhibition of these kinases can lead to reduced phosphorylation and activation of downstream proteins, including PLEKHH1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the activation of AKT signaling pathways, which may result in the inactivation of proteins associated with membrane dynamics like PLEKHH1. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A selective inhibitor of protein kinase C (PKC) isoforms. It hampers the PKC-mediated signaling, which is critical for the regulation of cytoskeletal organization where PLEKHH1 is implicated. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
A tyrosine kinase inhibitor which may block phosphorylation of proteins involved in cell adhesion and migration, processes that PLEKHH1 is known to be associated with. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
An irreversible inhibitor of PI3K. By inhibiting PI3K, it compromises the PI3K/AKT pathway, potentially affecting the localization and function of PLEKHH1 in cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK. By inhibiting p38 MAPK, this compound may influence stress response pathways, thereby affecting the stability and function of PLEKHH1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2 which are upstream of ERK in the MAPK pathway. Inhibition of this pathway could modify the cytoskeletal dynamics and cell adhesion where PLEKHH1 is involved. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK, which acts upstream of MAPK/ERK. By blocking this pathway, this compound can indirectly affect the stability and function of PLEKHH1 involved in cytoskeletal regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in the regulation of cytoskeletal architecture. Inhibition of JNK signaling could affect the function of PLEKHH1. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of ROCK kinases, which are involved in regulating actin cytoskeleton dynamics. Disruption of ROCK activity may impact the function of proteins like PLEKHH1 that are associated with cytoskeletal regulation. |